Metagenomi, Inc.
MGX
$2.07
$0.136.70%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 55.08M | 55.93M | 47.26M | 44.76M | 37.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 55.08M | 55.93M | 47.26M | 44.76M | 37.95M |
| Cost of Revenue | 110.77M | 111.35M | 105.71M | 94.40M | 84.71M |
| Gross Profit | -55.69M | -55.42M | -58.45M | -49.65M | -46.75M |
| SG&A Expenses | 32.78M | 33.06M | 31.13M | 28.85M | 27.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 143.55M | 144.42M | 136.84M | 123.25M | 112.01M |
| Operating Income | -88.47M | -88.49M | -89.59M | -78.49M | -74.06M |
| Income Before Tax | -75.53M | -73.27M | -71.44M | -60.23M | -57.44M |
| Income Tax Expenses | -1.58M | 1.73M | 5.83M | 8.03M | 6.15M |
| Earnings from Continuing Operations | -73.95 | -75.00 | -77.27 | -68.26 | -63.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.95M | -75.00M | -77.27M | -68.26M | -63.59M |
| EBIT | -88.47M | -88.49M | -89.59M | -78.49M | -74.06M |
| EBITDA | -83.33M | -83.55M | -84.95M | -74.29M | -70.34M |
| EPS Basic | -7.66 | -12.97 | -14.21 | -17.76 | -16.39 |
| Normalized Basic EPS | -4.33 | -7.42 | -8.23 | -10.05 | -9.53 |
| EPS Diluted | -7.66 | -12.97 | -14.21 | -17.76 | -16.39 |
| Normalized Diluted EPS | -4.33 | -7.42 | -8.23 | -10.05 | -9.53 |
| Average Basic Shares Outstanding | 97.93M | 64.57M | 36.44M | 18.70M | 18.70M |
| Average Diluted Shares Outstanding | 97.93M | 64.57M | 36.44M | 18.70M | 18.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
